Gunderson Dettmer represented client TCG Labs-Soleil in its inaugural fund of over $400 million. The TCG Labs-Soleil model combines TCG Labs Fund I and Soleil, an independent R&D hub led by a first-rate scientific team, to establish and oversee a suite of portfolio companies, each focused on individual single-asset programs. TCG Labs-Soleil aims to pioneer a venture-biotech model to efficiently translate scientific insights into therapeutic solutions for patients facing serious diseases.

TCG Labs – Soleil represents a collaboration with The Column Group, a premier science-driven venture capital firm focused on drug discovery.  In the announcement about the launch, TCG Labs managing partner Tim Kutzkey said, “The TCG Labs-Soleil model combines scientific, financial, and operational resources into one enterprise to enhance value creation. Further, it offers an investment strategy that complements TCG’s venture model, favoring an amalgam of single-asset programs over platform or pipeline approaches and building a single, exceptional R&D organization, rather than spreading resources across a portfolio of independent companies, each of which requires its own team.”

The Gunderson Dettmer team consisted of Andrew Thornborrow, Chris Partin, Amanda Chan, Casey Stevens and Kevin Harris.

Companies
TCG Labs-Soleil 
The Column Group